Hematological Oncology Collection
The AACR editors are proud to present this selection of impactful journal articles focusing on hematological oncology, published from across the AACR journal portfolio.
Transposon mutagenesis reveals fludarabine-resistance mechanisms in chronic lymphocytic leukemia.
Pandzic T, Larsson J, He L, Kundu S, Ban K, Akhtar-Ali M, et al. Clinical Cancer Research 2016; DOI: 10.1158/1078–0432.CCR–15–2903. [Published OnlineFirst March 8, 2016].
Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse.
Farrar JE, Schuback HE, Ries RE, Wai D, Hamptoet OA, Trevino OR, et al. Cancer Research 2016; DOI: 10.1158/0008–5472.CAN–15–1015. [Published OnlineFirst March 3, 2016].
Elevated translation initiation factor eIF4E is an attractive therapeutic target in multiple myeloma.
Li S, Fu J, Lu C, Mapara MY, Raza S, Hengst U, et al. Molecular Cancer Therapeutics 2016; DOI: 10.1158/1535–7163.MCT–15–0798. [Published OnlineFirst March 3, 2016].
SGK kinase activity in multiple myeloma cells protects against ER stress apoptosis via a SEK-dependent mechanism.
Hoang B, Shi Y, Frost PJ, Mysore V, Bardeleben C, Lichtenstein A. Molecular Cancer Research 2016; DOI:10.1158/1541–7786.MCR–15–0422. [Published OnlineFirst February 11, 2016.]
A novel recombinant anti-CD22 immunokinase delivers pro-apoptotic activity of death-associated protein kinase (DAPK) and mediates cytotoxicity in neoplastic B cells.
Lilienthal N, Lohmann G, Crispatzu G, Vasyutina E, Zittrich S, Mayer P, et al. Molecular Cancer Therapeutics 2016; DOI: 10.1158/1535–7163.MCT–15–0685. [Published OnlineFirst January 29, 2016].
Impact of treatment and insurance on socioeconomic disparities in survival after adolescent and young adult Hodgkin lymphoma: a population-based study.
Keegan THM, DeRouen MC, Parsons HM, Clarke CA, Goldberg D, Flowers CR, et al. Cancer Epidemiology, Biomarkers & Prevention 2016;25:264–73.
The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations.
Zhang W, Borthakur G, Gao C, Chen Y, Mu H, Ruvolo VR, et al. Cancer Research 2016;76:1528–37
A DNA-binding molecule targeting the adaptive hypoxic response in multiple myeloma has potent antitumor activity.
Mysore VS, Szablowski J, Dervan PB, Frost PJ. Molecular Cancer Research 2016; DOI: 10.1158/1541–7786.MCR–15–0361. [Published OnlineFirst January 22, 2016].
Myc induces miRNA-mediated apoptosis in response to HDAC inhibition in hematologic malignancies.
Adams CM, Hiebert SW, Eischen CM. Cancer Research 2016;76:736–48.
Bone marker–directed dosing of zoledronic acid for the prevention of skeletal complications in patients with multiple myeloma: results of the Z-MARK study.
Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, et al. Clinical Cancer Research 2016;22:1378–84.
Co-occurrence of myeloproliferative neoplasms and solid tumors is attributed to a synergism between cytoreductive therapy and the common TERT polymorphism rs2736100.
Krahling T, Balassa K, Kiss KP, Bors A, Batai A, Halm G, et al. Cancer Epidemiology, Biomarkers & Prevention 2016;25:98–104.
A phase II trial of AZD6244 (Selumetinib, ARRY-142886), an oral MEK1/2 inhibitor, in relapsed/refractory multiple myeloma.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, et al. Clinical Cancer Research 2016;22:1067–75.
Infection exposure is a causal factor in B-cell precursor acute lymphoblastic leukemia as a result of Pax5-inherited susceptibility.
Martín-Lorenzo A, Hauer J, Vicente-Dueñas C, Auer F, González-Herrero I, García-Ramírez I, et al. Cancer Discovery 2015;5:1328–43.
Chemopreventive effects of dietary eicosapentaenoic acid supplementation in experimental myeloid leukemia.
Finch ER, Kudva AK, Quickel MD, Goodfield LL, Kennett MJ, Whelan J, et al. Cancer Prevention Research 2015;8:989–99.
Mass cytometric functional profiling of acute myeloid leukemia defines cell-cycle and immunophenotypic properties that correlate with known responses to therapy.
Behbehani GK, Samusik N, Bjornson ZB, Fantl WJ, Medeiros BC, Nolan GP. Cancer Discovery 2015;5:988–1003.